Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Trading 05-06 10:10:09 EDT

1.63

-0.02

-1.21%

High1.66	Low1.62	Vol201.02K
Open1.66	D1 Closing1.65	Amplitude2.42%
Mkt Cap690.60M	Tradable Cap681.34M	Total Shares423.68M
T/O329.17K	T/O Rate0.05%	Tradable Shares418.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":1.63,"timestamp":1778076609322,"preClose":1.65,"halted":0,"volume":201021,"delay":0,"changeRate":-0.012121212121212133,"floatShares":418000000,"shares":423680611,"eps":-0.13866,"marketStatus":"Trading","change":-0.02,"latestTime":"05-06 10:10:09 EDT","open":1.66,"high":1.66,"low":1.62,"amount":329174.299752,"amplitude":0.024242,"askPrice":1.64,"askSize":2844,"bidPrice":1.63,"bidSize":2002,"shortable":3,"etf":0,"ttmEps":-0.13866,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778097600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":1.65,"preHourTrading":{"tag":"盘前","latestPrice":1.6605,"preClose":1.65,"latestTime":"09:20 EDT","volume":1866,"amount":3103.6054667999997,"timestamp":1778073605085,"change":0.0105,"changeRate":0.006364,"amplitude":0.006061},"postHourTrading":{"tag":"盘后","latestPrice":1.65,"preClose":1.65,"latestTime":"19:30 EDT","volume":1362,"amount":2246.83,"timestamp":1778023832205,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.395661,"impliedVol":1.2912,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/LXRX/tweets","defaultTab":"tweets","newsList":[{"id":"2633994844","title":"Lexicon Pharmaceuticals Inc  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633994844","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633994844?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:32","pubTimestamp":1777984353,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc  expected to post a loss of3cents a share - Earnings Preview Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to  show a rise in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965879","title":"Lexicon Pharmaceuticals : Loan Facility Provides for an Initial Interest-Only Period of 18 Months, With Potential for Two Six-Month Extensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965879?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3QP8DM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4135","BK4139","HTGC","BK4007","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963787","title":"Lexicon Pharmaceuticals Announces $100 Million Loan Facility With Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963787?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3QP8DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","LXRX","BK4135","HTGC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633585965","title":"Lexicon Pharmaceuticals: Under Terms, Initial $55 Mln Tranche Will Be Used to Repay Existing Loan Facility With Oxford Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2633585965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633585965?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3QP8DM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HTGC","BK4139","LXRX","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965507","title":"Press Release: Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965507?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, May 04, 2026  -- Lexicon Pharmaceuticals, Inc.  announced today that it has entered into a loan facility with Hercules Capital, Inc.  that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.\"Hercules Capital is pleased to support Lexicon Pharmaceuticals with a flexible financing solution that will support it through upcoming clinical and regulatory milestones,\" said Adam Soller, Managing Director. \"This partnership underscores our commitment to funding innovative therapies that address significant unmet medical needs.\". Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4531","BK4588","BK4007","HTGC","BK4135","BK4585","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669305","title":"Lexicon Pharmaceuticals shareholders approved increase in authorized common shares to 900 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669305","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669305?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:26","pubTimestamp":1777580798,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals held annual shareholder meeting April 30, 2026.Shareholders backed Seventh Amended and Restated Certificate of Incorporation, lifting authorized common stock to 900 million shares from 450 million shares.Stockholders also adopted 2026 Equity Incentive Plan, raising share pool to 90 million shares from 75 million shares.Vote also adopted 2026 Non-Employee Directors' Equity Incentive Plan, increasing share pool to 6 million shares from 4 million shares.Ernst & Young was ratified as independent auditor for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3ynd6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634938","title":"Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634938","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634938?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, April  30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, Ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284770/0/en/Lexicon-Pharmaceuticals-to-Report-First-Quarter-2026-Financial-Results-on-May-7-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","LXRX","BK4585","BK4531","HCM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628020529","title":"Lexicon says Phase 2b data support pilavapadin 10 mg for Phase 3 DPNP trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628020529","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628020529?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:03","pubTimestamp":1776427420,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals scheduled new Phase 2b PROGRESS data on pilavapadin in diabetic peripheral neuropathic pain for presentation April 22 at American Academy of Neurology annual meeting in Chicago.Updated findings supported selection of 10 mg as dose for Phase 3 development, based on improved patient-reported pain outcomes versus placebo.Tolerability profile for 10 mg over eight weeks remained broadly comparable to placebo, with few treatment-related discontinuations.Additional preclinical results on pilavapadin in spasticity models of multiple sclerosis or spinal cord injury are set for poster presentation April 20, expanding focus on AAK1 pathway in neurologic disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL8ssTdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4139","BK4588","BK4007","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","LXRX","LU2095319765.USD","SG9999014005.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064606","title":"Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064606","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064606?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:05","pubTimestamp":1774353906,"startTime":"0","endTime":"0","summary":"Lexicon announced three presentations of sotagliflozin clinical data that will be presented at the American College of Cardiology Annual Scientific Session & Expo in New Orleans, held March 28-30.One presentation will report a prespecified Phase 3 SCORED analysis stratified by baseline body mass index, showing reductions in heart failure and major adverse cardiovascular events irrespective of BMI.Two additional presentations will report analyses from the randomized, double-blind, placebo-controlled SOTA-P-CARDIA trial in symptomatic HFpEF patients without diabetes, including improved health-related quality of life and physical limitation versus placebo.Another SOTA-P-CARDIA analysis will describe findings on selective reduction of epicardial adipose tissue and hepatic fat with sotagliflozin.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3nxbz9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LXRX","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","BK4112","SG9999014013.SGD","BK4139","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU0314104364.USD","BK4007","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210150020.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621970746","title":"Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2621970746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621970746?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:30","pubTimestamp":1774279800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 11:30 ET (15:30 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702802","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702802?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:30","pubTimestamp":1774276207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4585","BK4137","HCSG","XLV","LU0029874061.USD","BK4007","LXRX","LU0128526141.USD","BK4581","BK4139","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708289","title":"Lexicon, Novo Nordisk announce initiation of LX9851 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708289?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:46","pubTimestamp":1774266397,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-novo-nordisk-announce-initiation-of-lx9851-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-novo-nordisk-announce-initiation-of-lx9851-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139","LU0154236417.USD","BK4588","NVOX","BK4585","NVO","LU1093756168.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4532","NVOH","IE00BKVL7J92.USD","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770768","title":"Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770768","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770768?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:31","pubTimestamp":1774265471,"startTime":"0","endTime":"0","summary":"Novo Nordisk initiated a Phase 1 clinical study of LX9851, an oral non-incretin drug candidate licensed from Lexicon for obesity and associated metabolic disorders.The trial is evaluating safety and tolerability, and it includes 96 participants with overweight or obesity.The study is also assessing pharmacokinetics and pharmacodynamics using single and multiple ascending doses versus placebo.Results have not been presented, and the trial is expected to be completed in Q1 2027.Lexicon earned a USD 10.0 million milestone payment tied to initial dosing and may receive up to USD 1.0 billion in total upfront and milestone payments under the agreement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2vYThN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","BK4585","BK4007","IE00BGHQF748.EUR","LXRX","BK4588","NDAQ","LU0314104364.USD","SG9999014021.USD","BK4139","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770202","title":"Lexicon Pharmaceuticals Inc - Phase 1 Study of Lx9851 Expected to Complete in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770202?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B06U:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702737","title":"Lexicon Pharmaceuticals and Novo Nordisk Announce Initiation of Phase 1 Study With Oral Obesity Drug Candidate Lx9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702737?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B06U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702727","title":"Lexicon Pharmaceuticals Inc - Earns Second $10 Mln Milestone; Eligible for up to $1 Bln in Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702727?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B06U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619153251","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619153251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619153251?lang=en_us&edition=fundamental","pubTime":"2026-03-13 00:40","pubTimestamp":1773333608,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rapid Micro Biosystems (RPID – Research Report), Lexicon Pharmace...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rapid-micro-biosystems-rpid-lexicon-pharmaceuticals-lxrx-and-whitehawk-therapeutics-whwk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rapid-micro-biosystems-rpid-lexicon-pharmaceuticals-lxrx-and-whitehawk-therapeutics-whwk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","HCSG","XBI","RPID","BK4139","BK4539","BK4121","WHWK","BK4588","LU0128526141.USD","XLV","LXRX","LABU","LU0029874061.USD","BK4007","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618942438","title":"Lexicon announces results from post hoc analysis on data of sotagliflozin","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942438?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:17","pubTimestamp":1773231437,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-on-data-of-sotagliflozin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-on-data-of-sotagliflozin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618442219","title":"Lexicon to present sotagliflozin kidney function analysis at ATTD conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618442219","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618442219?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:02","pubTimestamp":1773230577,"startTime":"0","endTime":"0","summary":"Lexicon to present sotagliflozin kidney function analysis at ATTD conference               Lexicon will present results from a post hoc analysis of sotagliflozin in type 1 diabetes as a short oral pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL90jCBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014039.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","LXRX","BK4585","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","BK4007","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618695106","title":"Lexicon Pharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2618695106","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618695106?lang=en_us&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 11:02 ET (15:02 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0377},{"period":"3month","weight":0.2992},{"period":"6month","weight":0.1538},{"period":"1year","weight":1.2917},{"period":"ytd","weight":0.4348}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.040884},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.046623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016324},{"month":4,"riseRate":0.461538,"avgChangeRate":0.013505},{"month":5,"riseRate":0.518519,"avgChangeRate":0.028934},{"month":6,"riseRate":0.653846,"avgChangeRate":0.134775},{"month":7,"riseRate":0.5,"avgChangeRate":0.021487},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction